CIK 0001735438 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 81.4 M | 14.0 M | ||
| Net income (USD) | -129.6 M | -79.6 M | ||
| Diluted EPS (USD/shares) | -1.42 | -1.49 | -2.87 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-20 | 4 | 4 | 2026-10-20 |
| 2026-10-20 | 144 | 144 | |
| 2026-10-06 | 4 | 4 | 2026-10-06 |
| 2026-10-06 | 144 | 144 | |
| 2026-09-24 | 4 | 4 | 2026-09-23 |
| 2026-09-24 | 3 | 3 | 2026-09-23 |
| 2026-09-23 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-09-22 |
| 2026-08-18 | 4 | 4 | 2026-08-18 |
| 2026-08-18 | 144 | 144 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | S-8 | S-8 | |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-07-21 | 4 | 4 | 2026-07-21 |
| 2026-07-21 | 144 | 144 | |
| 2026-07-07 | 4 | 4 | 2026-07-07 |
| 2026-07-07 | 144 | 144 | |
| 2026-07-07 | 8-K | 8-K items 1.01,1.02,2.03,3.02,7.01,9.01 | 2026-06-30 |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
Forms on file (last 1,000): 4 224, 8-K 83, 10-Q 25, 3 23, 144 17, SC 13G/A 14, DEFA14A 9, DEF 14A 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MGTX (0.002 USD), /gw/filings/filings?ticker=MGTX&form=8-K, /gw/filings/facts?ticker=MGTX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange